Laboratorio IBC is an Argentine capital company exclusively dedicated to the production of injectable medicinal specialties for the national and international pharmaceutical industry. Since its founding in 1989 in the Autonomous City of Buenos Aires, IBC has pursued a growth and continuous improvement-based policy. The company now boasts two new state-of-the-art plants in Ituzaingó, Buenos Aires. One of these plants, inaugurated in 2007, is dedicated exclusively to the production of lyophilized products, while the newly segregated plant is solely for the production of sterile β-lactam powders. From the outset, IBC has been committed to providing quality services to its customers. The company employs 12 pharmaceutical professionals, along with qualified personnel and the necessary machinery, facilities, and equipment to operate under strict Good Manufacturing Practices (GMP) standards governing the pharmaceutical industry. Since 1997, IBC has implemented an Investment Plan in equipment and facilities, enabling market expansion to Latin American and Asian countries. The company currently holds local certifications, such as ANMAT, and international certifications, including MERCOSUR and INVIMA (Colombia). This successful dedication to high standards is evident in the recertification of the Mercosur for its Liofilizados Injectable Plant in Ituzaingó by ANMAT in October 2013. Founded in 1989, the company operates in the Manufacturing and Pharmaceutical industries from its headquarters in Argentina. Although specific investment details are not provided, Laboratorio IBC presents a compelling case for potential investors looking to engage in the pharmaceutical manufacturing sector within Argentina and beyond.
There is no investment information
We care about your data, and we'd love to use cookies make your experience better.
